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Introduction:  Epidermal  growth  factor  receptor  (EGFR)-tyrosine  kinase  inhibitor  (TKI)  treatment  is  the
standard  therapy  for non-small  cell  lung  cancer  (NSCLC)  harbouring  EGFR-activating  mutations.  The
NEJ002  phase  3 clinical  trial demonstrated  the  efﬁcacy  of EGFR-TKI;  geﬁtinib  was  signiﬁcantly  superior
in  both  progression-free  survival  (PFS)  and  objective  response  rate  (ORR)  than  carboplatin  plus  pacli-
taxel.  However,  several  cases  showed  no  response.  In this  study,  we performed  further  analysis  of  the
characteristics  of  these  non-responders.
Methods:  Available  data  from  NEJ002  on maximum  changes  in tumour  size  were  obtained  from  103 cases
(90.4%)  and 110  cases  (96.5%)  in  the  carboplatin–paclitaxel  and  geﬁtinib  groups,  respectively.  Waterfall
plots  of maximum  tumour  size  changes  were  created  for non-responders.
Results:  Five  (4.9%)  and  9 (8.2%)  cases  in the  carboplatin–paclitaxel  and  geﬁtinib  groups  were  non-
responders,  respectively.  The  mean  pack  years  of  the  non-responders  in  the  carboplatin–paclitaxel  and
geﬁtinib  groups  were  0.33  and  31.7,  respectively.  The  ORR  of  total smokers  (61.5%)  and  heavy  smok-
ers  (over  40  pack  years,  52.6%)  in the geﬁtinib  group  were  signiﬁcantly  lower  compared  to  people  who
have  never  smoked  (80.0%)  (P = 0.044  and  P  = 0.020,  respectively).  Smoker  cases  also  showed  a tendency
towards  lower  PFS  and  overall  survival  (OS).  In addition,  the  EGFR  common  mutation  types  did  not  affect
PFS  and  OS  in  geﬁtinib-treated  cases  in  NEJ002.  However,  in  this  study,  the  ORR  and  waterfall  plots
showed  that  geﬁtinib-treated  non-responders  who  had  a deletion  in  exon  19  in the EGFR  gene  exhibited
a  tendency  towards  a higher  response  compared  to  those  with a L858R  mutation.
Conclusions:  NSCLC  patients  w
poorer  response  to  geﬁtinib  tr
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. Introduction
Lung cancer is the leading cause of cancer death worldwide.
ost lung cancer patients are diagnosed in the advanced stages
f the disease; thus, despite a signiﬁcant improvement in the treat-
ent for this malignancy, the prognosis remains poor [1]. Recent
tudies have demonstrated driver gene mutations, which promote
he development of lung cancer [2]. In 2004, epidermal growth fac-
or receptor (EGFR)-activating mutations were discovered in lung
ancer by two different groups [3,4]. Subsequently, EGFR-TKI treat-
ent was established as the standard treatment for lung cancer
arbouring EGFR mutations based on the results of pivotal trials
5,6].
Currently, the clinically available EGFR-TKIs are geﬁtinib,
rlotinib, and afatinib. In Japan, the North East Japan Study Group
NEJ) demonstrated the efﬁcacy of geﬁtinib treatment [6]. This
tudy revealed signiﬁcantly higher objective response rates (ORR)
nd longer progression-free survival (PFS) of patients with geﬁti-
ib treatment compared to patients treated with carboplatin plus
aclitaxel, which is the standard cytotoxic chemotherapy (73.7%,
0.8 months vs. 30.7%, 5.4 months, respectively) [6,7]. Although
here was no difference in overall survival (OS) (27.7 months for
he geﬁtinib group vs. 26.6 months for the carboplatin plus pacli-
axel group), this was assumed to be due to a high crossover rate
ecause geﬁtinib was administered as a second-line therapy to
ost patients who received unsuccessful ﬁrst-line chemotherapy
7]. Smoking history and type of EGFR common mutations (exon
9 deletion or L858R point mutation) did not affect the OS of each
reatment group [7].
Geﬁtinib treatment for EGFR mutation-positive lung cancer
emonstrated a signiﬁcantly higher ORR; however, we observed
everal cases that showed a poor treatment response. Using data
ollected from the pivotal NEJ002 study, we analysed the charac-
eristics of these poor response cases or non-responders.
. Methods
.1. Patient population
This was a retrospective analysis of clinical data obtained from
30 patients from the NEJ002 study. The eligibility criteria were
reviously described in the NEJ002 study [6]. Brieﬂy, the crite-
ia included the presence of advanced non-small cell lung cancer
NSCLC) harbouring sensitive EGFR mutations, the absence of the
esistant EGFR mutation T790M (in which threonine at amino acid
90 was substituted by methionine), no history of chemotherapy,
nd an age of 75 years or younger. From March 2006 to May  2009,
30 patients were enrolled in the NEJ002 study.
.2. Study design and treatment
After the exclusion of 2 patients, geﬁtinib was administered to
14 patients, and the other 114 patients were allocated to receive
arboplatin plus paclitaxel. Prior to randomisation, patients were
tratiﬁed according to sex, clinical stage of NSCLC (IIIB, IV, or
ostoperative relapse), and institution. Eligible patients were ran-
omly assigned to receive geﬁtinib (at a dose of 250 mg  per day
rally) or carboplatin (at a dose equivalent to an area under the
oncentration–time curve of 6) plus paclitaxel (at a dose of 200 mg
er square metre of body surface area). Geﬁtinib was  adminis-
ered until disease progression, development of intolerable toxic
ffects, or withdrawal of consent. Carboplatin plus paclitaxel were
oth administered on the ﬁrst day of every 3-week cycle for at
east three cycles. Retrospective analysis was performed using the
urrently available data. The available data on maximum changeser 88 (2015) 181–186
in the tumour target lesion size from baseline were evaluated in
103 patients (90.4%) and 110 patients (96.5%) in the carboplatin
plus paclitaxel and geﬁtinib groups, respectively. Seven patients in
the carboplatin plus pactlitaxel group and 1 patient in the geﬁt-
inib group could not be evaluated for treatment response [6].
The remaining 4 patients in the carboplatin plus paclitaxel group
and 3 patients in the geﬁtinib group showed that the tumour
progression after each treatment made the tumour-target-lesion
immeasurable. Progression of atelectasis or increased pleural effu-
sion occurred in most of the cases.
2.3. Clinical assessments
An assessment of the maximum changes in tumour size was
performed using data for the evaluation of ORR with computed
tomography (CT) every 2 months. Unidirectional measurements
were adopted on the basis of the Response Evaluation Criteria In
Solid Tumours (RECIST, version 1.0). We  deﬁned a non-responder
as a patient whose tumour-target-lesion size showed no change
or increased despite the administration of each treatment during
complete ﬁrst-line treatment. Treatment response and PFS were
determined by an external review of the CT scans by experts who
were blinded to the treatment assignments. OS was evaluated for
the period from the date of randomisation to the date of death.
2.4. Statistical analysis
The smoking pack years between two the groups were com-
pared using the Wilcoxon rank sum test. The ORR  was compared
using Fisher’s exact test. Kaplan–Meier survival curves were drawn
for PFS and OS and were compared using the log-rank test. Each
analysis was performed using a two-sided, 5% signiﬁcance level and
a 95% conﬁdence interval using SAS for Windows software (release
9.1.3, SAS Institute, Cary, NC).
3. Results
3.1. Fourteen cases showed no response to either treatment
Waterfall plots showing maximum changes in the tumour
target lesion size from baseline are indicated in Fig. 1A
(lower). As previously demonstrated in the NEJ002 study, in
which geﬁtinib treatment showed a higher response rate than
carboplatin–paclitaxel treatment, the geﬁtinib group had more
cases that showed a partial and complete response to the treatment
compared to the carboplatin–paclitaxel group. However, 5 patients
(4.9%) in the carboplatin–paclitaxel group and 9 patients (8.2%) in
the geﬁtinib group showed no response and instead experienced
no decrease in tumour size or an increased tumour size (Table 1).
We analysed the characteristics of these non-responder cases for
speciﬁc predictive factors of response to treatment.
3.2. Non-responders to geﬁtinib treatment showed a tendency
towards higher smoking pack years than the carboplatin plus
paclitaxel group
The number of smoking pack years of each case is indicated in
Fig. 1A (upper). When only non-responders were evaluated, those
in the geﬁtinib treatment group showed a tendency towards higher
smoking pack years. The mean pack years of cigarette smoking of
the non-responders in the carboplatin plus paclitaxel and geﬁtinib
groups were 0.3 and 31.7, respectively (P = 0.164. Fig. 1B).Among the 9 non-responders of the geﬁtinib treatment group, 4
of the subjects were never smokers (Table 1). Case GC-007 showed
a long duration of stable disease, which indicated the partial efﬁ-
cacy of geﬁtinib. Case GC-054 had an exon 18 minor mutation in
T. Fukuhara et al. / Lung Cancer 88 (2015) 181–186 183
Fig. 1. (A) Lower: maximum changes in the target lesion size from the baseline of each case in the NEJ002 study were demonstrated using waterfall plots. The black line
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he EGFR gene. Our group previously published data on the poor
reatment response to geﬁtinib in patients with minor mutations
8]. Both case GC-194 and case GC-063 discontinued geﬁtinib treat-
ent due to serious adverse event, including drug-induced lung
isease and liver dysfunction, respectively. In contrast, among the
emaining 5 patients who had a smoking history, only 1 patient had
n exon 18 minor mutation, and the other patients had no episodes
f serious adverse events. In the carboplatin plus paclitaxel group,
nly 1 patient ceased the ﬁrst-line treatment due to the onset of
leus, and the remaining non-responders did not show any speciﬁc
linical characteristics.
.3. PFS and OS of the geﬁtinib-treated smoker group showed a
endency towards poor prognosis
The ORR of the geﬁtinib group was 73.7% [6]. When divided into
 groups by smoking history, the ORR of the smoker group was
igniﬁcantly lower than the never smoker group (61.5% vs. 80.0%,
 = 0.044, Table 2). Moreover, the ORR of the heavy smoker group
over 40 pack years) was 52.6% and signiﬁcantly lower than the
on-smoker group (P = 0.020).
Kaplan–Meier curves of the PFS and OS are shown in Fig. 2A and
. Although not statistically signiﬁcant, the smoker cases showed a
able 1
ndividual non-responders cases from NEJ002. Non-responder denotes patients who  neve
Case No. Maximum
changea
Sex Age ECOG-PS Histology Stage 
Carboplatin + paclitaxel
GC-068 +9.7 Female 72 1 AD IV 
GC-176 +2.7 Female 69 1 AD IV 
GC-001 0 Female 72 1 AD IV 
GC-077  0 Male 71 1 AD IV 
GC-220 0 Male 75 1 AD IV 
Geﬁtinib
GC-007 +33.3 Female 70 1 AD IIIB 
GC-011 +32.1 Male 56 1 AD Relapse 
GC-194 +22.2 Female 60 1 AD IV 
GC-054  +21.1 Male 68 1 AD IV 
GC-158 +8.8 Male 65 0 AD IV 
GC-183 +7.8 Male 63 0 AD IIIB 
GC-195  +7.6 Male 51 1 AD IV 
GC-031 +2.4 Male 64 1 AD IV 
GC-063 0 Female 67 0 AD-SQC IIIB 
D: adenocarcinoma; AD-SQC: adenosquamous carcinoma; PD: progressive disease; SD: 
a Maximum change from baseline during the ﬁrst-line treatment (%).
b Duration from entry to maximum size (month).r: smoking pack years of each case. (B) Smoking pack years of non-responder cases
tendency towards lower PFS and OS compared to the non-smoker
cases (P = 0.074 and P = 0.164, respectively).
3.4. NSCLC patients with the EGFR L858R mutation showed a
relatively poor response to geﬁtinib compared to patients with an
exon 19 deletion mutation
Although we previously reported the PFS and OS of the
geﬁtinib treated exon 19 deletion mutant group did not show
any difference compared to the L858R mutation group [6,7],
the types of EGFR mutations may  also be an important pre-
dictive factor of the treatment response, as shown in Table 1,
which depicts the non-responders’ EGFR mutation status. Namely,
three non-responders (GC-007, 011, 194) with geﬁtinib treat-
ment, who showed increases of over 20% in tumour growth
from baseline, had a L858R mutation. A comparison of the
patients based on EGFR common activating mutations, L858R
and exon 19 deletion, revealed that ORR (Table 3) and the max-
imum tumour size changed from baseline (Fig. 3A and B) in
geﬁtinib-treated patients and indicated that the L858R muta-
tion was worse than an exon 19 deletion mutation. In contrast,
patients who received carboplatin plus paclitaxel did not show any
differences.
r had decrease in the size of measurable lesion during ﬁrst-line treatment.
EGFR mutation Smoking pack
years
Response Durationb OS (month)
Exon 19 deletion 0 PD 0.9 43.7
Exon 19 deletion 0 SD 1.6 25.6
G719S 0 SD 1.9 9.8
Exon 19 deletion 0 SD 1.7 16.4
Exon 19 deletion 1.65 NE 0.8 20.6
L858R 0 SD 22.0 53.6
L858R 60 PD 2.3 21.9
L858R 0 PD 1.1 1.7
G719 C 0 PD 1.9 11.8
Exon 19 deletion 40 SD 2.3 27.6
Exon 18 86 PD 2.2 5.7
Exon 19 deletion 62 PD 2.0 10.9
Exon 19 deletion 37.5 PD 0.3 10.8
Exon 19 deletion 0 SD 1.2 37.1
stable disease; NE: not evaluated.
184 T. Fukuhara et al. / Lung Cancer 88 (2015) 181–186
Table 2
Response of cases categorised by smoking history in the geﬁtinib treatment group.
CR: complete response; PR: partial response; PD: progressive disease; SD: stable disease; NE: not evaluated.
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he  log-rank test. (A) PFS. (B) OS.
. Discussion
For NSCLC cases with an EGFR mutation, geﬁtinib treatment
ncreased both the ORR and PFS more than carboplatin plus pacli-
axel treatment. Nevertheless, the number of non-responders to
eﬁtinib treatment was also higher compared to patients treated
ith carboplatin plus paclitaxel, 9 (8.1%) vs. 5 (4.4%), respectively.
nterestingly, non-responders of the geﬁtinib group, who had nei-
her a serious adverse event nor minor EGFR mutations, had a
moking history. This result indicates that a smoking history may
e an important predictive factor for geﬁtinib treatment. The type
f EGFR-activating mutation may  also be another predictive fac-
or for the response to geﬁtinib treatment; NSCLC patients with a
858R mutation exhibited a poorer response to geﬁtinib compared
o patients with an exon 19 deletion mutation.
Most of the EGFR-mutant patients who had a smoking history
r L858R mutation showed a better response to geﬁtinib comparedf the NEJ002 study, as described by the Kaplan–Meier method and compared using
to carboplatin plus paclitaxel. However, the response rate was
signiﬁcantly lower, particularly in the heavy smoker group com-
pared to the non-smoker group.
Several studies indicated that NSCLC patients harbouring EGFR
mutations with many smoking pack years showed a relatively
poor response to EGFR-TKI treatment [9–11]. Several mechanisms
have been proposed to explain the poorer response to EGFR-TKI
in patients with a smoking history. One group found that cigarette
smoking induced EGFR posttranslational changes [12] and that the
Src oncogene may  confer resistance to treatment [13]. Another
group demonstrated that activation of the nicotinic acetylcholine
receptor by cigarette smoking induced EGFR-TKI resistance [14].
Furthermore, many chemicals contained in cigarette smoke have
a high activity of mutagenesis [15]. Consistent with this ﬁnding,
the rate of gene alteration in smoker patients with NSCLC har-
bouring EGFR mutations was  considerably higher compared to
non-smokers [16,17]. Moreover, lung cancer cells derived from lung
T. Fukuhara et al. / Lung Cancer 88 (2015) 181–186 185
Table  3
Response of cases categorised by the types of EGFR common mutation.
CR: complete response; PR: partial response; PD: progressive disease; SD: stable disease; NE: not evaluated.
F the ca
i  deleti
o
o
m
d
a
t
[
m
f
f
b
t
o
E
w
t
i
h
[
had a smoking history showed a signiﬁcantly lower response rateig. 3. Maximum changes in the target lesion size from the baseline of each case in 
nto  2 groups according to the type of EGFR common mutation, L858R and exon 19
f heavy smokers contained “driver” EGFR mutations and many
ther “passenger” gene mutations. These passenger genes may
odify signal transduction pathways that render cell death more
ifﬁcult to be induced by treatment with EGFR-TKI alone.
Recently, treatment of other clinically available EGFR-TKI, such
s erlotinib and afatinib, in NSCLC patients with an exon 19 dele-
ion showed a higher response than those with the L858R mutation
18,19]. However, for geﬁtinib phase 3 studies, the type of EGFR
utation did not affect PFS and OS [5–7]. In the present study, we
ound that geﬁtinib treatment also showed a tendency towards a
avourable response in patients with an exon 19 deletion mutation
ased on an evaluation of short-term responses, such as ORR and
he maximum change in tumour size from baseline. If the response
f geﬁtinib treatment was affected by EGFR subtypes, then all three
GFR-TKIs demonstrated a higher treatment response in patients
ith an exon 19 deletion compared to those with the L858R muta-ion to varying degrees. There was no difference in the half maximal
nhibitory concentration (IC50) of geﬁtinib given to cancer cell lines
arbouring an exon 19 deletion and those with the L858R mutation
20,21]. However, a recent study revealed that the crystal structurerboplatin plus paclitaxel (A) and geﬁtinib (B) groups. The patients were categorised
on.
of the L858R mutation is more stable in maintaining the active form
than the exon 19 deletion mutation [22]. The rationale underlying
these differences in response to EGFR-TKI may  be explained by their
activating mechanism.
In this study, we  found candidate predictive factors of the
response to geﬁtinib treatment. Due to the high efﬁcacy of geﬁt-
inib treatment, the number of non-responders was very small. To
conﬁrm the results of this study, additional data on non-responders
to EGFR-TKI treatment should be collected for further analysis.
5. Conclusion
In this study, on the basis of the characteristics of non-
responders to geﬁtinib in the NEJ002 study, we found two potential
factors for a poor response to EGFR-TKI treatment. Patients whoto geﬁtinib treatment. Geﬁtinib treatment may  be more effective in
patients with an exon 19 deletion than those with the L858R muta-
tion. To clarify these relationships, further studies using additional
data on non-responders are needed.
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